French drugmaker Servier has outlicensed some early-stage cancer treatments to Horizon Discovery, holding on to the rights to buy them back if they come through in preclinical development. Under the deal, Horizon gets a handful of novel kinase inhibitors for a range of cancer types, planning to use its screening platform to find ideal patient populations for each. Servier has the right to license back the treatments for as much as £50 million ($76.6 million) in milestone payments, and if it chooses not to, Horizon is free to find another pharma partner. Release